Business Wire

SES Selects Arianespace to Launch EAGLE-1 Satellite for Europe’s Quantum Cryptography

9.11.2022 10:50:00 EET | Business Wire | Press release

Share

The EAGLE-1 satellite, which will support the end-to-end secure Quantum Key Distribution (QKD) system for Europe, will be launched for SES by Arianespace on a Vega C rocket from French Guiana as early as Q4 2024. The satellite will be placed into Low Earth Orbit (LEO). The EAGLE-1 project comprising satellite and ground infrastructure, is developed by SES and its consortium of 20 European partners, with the European Space Agency (ESA) and the European Commission support.

Under the recently-signed agreement with ESA, SES and its partners will design, develop, launch and operate a satellite-based end-to-end QKD system for the purpose of testing and validating space-based secure transmission of cryptographic keys. The first European sovereign space-based QKD system will include the dedicated low earth orbit (LEO) EAGLE-1 satellite and state-of-the-art QKD operations centre in Luxembourg. In the scope of EuroQCI, the EAGLE-1 satellite will enable early access, validation, and integration of space-based QKD for EU Member States.

“Building the EAGLE-1 end-to-end system for secure data transmission and validating the long-distance Quantum Key Distribution technology is an innovative project that will benefit the EU Member States,” said Ruy Pinto, Chief Technology Officer at SES. “We have been working with Arianespace for decades to deliver our satellites into space and are delighted for them to be onboard to launch the EAGLE-1 satellite into orbit.”

“We are delighted and honored by this renewed mark of confidence from the leading global content connectivity service provider SES,” noted Marino Fragnito, Director of Arianespace’s Vega business unit. “Over the last 38 years, Arianespace has carried out 42 launches for its longstanding partner, and Vega C will now continue this successful track record. It is a great honor for us to support our customer’s ambitions and to be part of this mission that aims at implementing Europe’s satellite-enabled cybersecurity technology.”

Following the launch, the EAGLE-1 satellite will complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions, as well as critical business sectors, early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.

The EAGLE-1 project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.

Vega C, the new European light launcher successfully passed its inaugural flight on July 13 and now enters its operational phase under the responsibility of Arianespace. With this contract, Vega C backlog includes over 40 satellites contracts.

Vega C development program has been managed by ESA with 12 Member States of the Agency. Avio Spa (Colleferro, Italy) is the industrial prime of the Vega launch system. Vega C has been upgraded with more powerful first and second stage Solid Rocket Motors and with a larger fairing, which significantly increases payload mass and double allowable volume as compared to Vega. The launcher also better meets the specific needs of small spacecrafts, thanks to its improved SSMS dispenser and to its AVUM+ that allows seven re-ignitions instead of five. Vega C can thus deliver to three different separation orbits for its multiple payloads within the same mission, instead of the two previously possible with Vega.

For more information, visit the EAGLE-1 Newsroom

Follow SES on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

Follow Arianespace on:

Twitter | YouTube | LinkedIn | Instagram

About ESA

The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int

The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

About Arianespace

Arianespace uses Space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited over 1,100 satellites since 1980. Arianespace is responsible for operating the new-generation Ariane 6 and Vega C launchers, developed by ESA, with respectively ArianeGroup and Avio as industrial primes. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 15 other shareholders from the Ariane and Vega European launcher industry, and ESA and Cnes as censors.

www.arianespace.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Suzanne Ong
External Communications, SES
Tel. +352 710 725 500
suzanne.ong@ses.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release

ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin

IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye